P

Precede Biosciences

Epigenomic liquid biopsy for cancer.

Associate Scientist / Scientist 1 - Computational Test Development

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeBoston, MA, USA$110k - $150k /yr

About the Job

Requirements

  • A Master of Science in computational biology, bioinformatics, biostatistics, or a closely related quantitative field, with 3–4 years of industry or post-graduate research experience in a data-intensive biological or biomedical setting.
  • Strong proficiency in R and Python for data analysis, visualization, and reproducible reporting, including writing, owning, and documenting code.
  • Experience with cloud computing environments such as AWS for running scalable analyses.
  • Ability to execute analytical plans precisely and efficiently, manage multiple tasks, and maintain quality and documentation standards.
  • Familiarity with next-generation sequencing data types and standard processing pipelines, including alignment, quality control, and coverage analysis, or equivalent.
  • Ability to produce clear written documentation, present results, and communicate across functions.
  • Comfort working in a fast-paced startup environment, following defined protocols while contributing ideas for improvement.

Responsibilities

  • Execute data analyses supporting assay characterization across multiple epigenomic and next-generation sequencing-based diagnostic tests, from raw data processing through performance metric generation.
  • Design and implement quality assessment frameworks to evaluate assay and pipeline performance, including quality control metric definition, threshold setting, and failure mode identification.
  • Run and interpret validation experiments in close coordination with wet lab and senior computational team members, contributing to study execution against predefined protocols.
  • Pursue defined research questions semi-independently by taking a scoped problem, designing the analytical approach, executing it, and returning well-documented results.
  • Design and run in silico simulations to model assay behavior under variable conditions, including signal dropout, coverage non-uniformity, and input DNA variability.
  • Develop and apply statistical approaches to threshold setting and performance boundary definition, supporting limit of detection and analytical range characterization.
  • Systematically explore parameter sensitivity across bioinformatics pipelines to assess model robustness and inform feature selection.
  • Produce clear, thorough documentation of analyses, code, methods, results, and interpretation to the standard required under design controls.
  • Contribute to authoring standard operating procedures and analytical summary reports.
  • Partner with wet lab scientists to ensure computational analyses are grounded in experimental reality and results are communicated in accessible, actionable terms.
  • Present analytical findings clearly in team meetings and cross-functional settings.
  • Share code and knowledge openly and proactively to contribute to a collaborative team environment.

Desired Qualifications

  • A Ph.D. is preferred.
  • Exposure to regulated environments such as CLIA, CAP, FDA in vitro diagnostics, or design controls.
  • Experience with epigenomic data types such as methylation, cell-free DNA, chromatin accessibility, or ChIP-seq.
  • Familiarity with statistical thresholding or limit of detection frameworks for diagnostic applications.
  • Experience contributing to standard operating procedures, validation reports, or other regulated documentation.

About the Company

Precede Biosciences

Epigenomic liquid biopsy for cancer.

Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.

Company size
51-200
Company stage
Series B
Total funding
$140.5M
Headquarters
Boston, MA
Founded
2021

Recently Posted Jobs

Explore more opportunities at Precede Biosciences

See more jobs